NOAEL Studies
Cosmetic Ingredient
Piperine NOAEL Studies
INCI: PIPERINE
CAS: 94-62-2
Raw No Observed Adverse Effect Level endpoint records grouped by source. This page does not render calculated Margin of Safety values.
COSMOS_DB 7 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| COSMOS_DB | NOAEL | 89.1 | mg/kg bw/day | mouse | oral | NA | Neurotoxicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 350 | mg/kg bw/day | rat | oral | 7 day | Short Term Toxicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 25 | mg/kg bw/day | mouse | oral | 4 day | Developmental | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 5 | mg/kg bw/day | rat | oral | 30 day | Short Term Toxicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 10 | mg/kg bw/day | mouse | oral | 14 day | Reproductive | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 75 | mg/kg bw/day | mouse | oral | 5 day | Special Toxicology Study | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
| COSMOS_DB | NOAEL | 1.12 | mg/kg bw/day | mouse | oral | 5 day | Short Term Toxicity | US FDA CFSAN PAFA; US FDA CFSAN PAFA Study |
EFSA_OpenFoodTox_EFSA_ReferencePoints.xlsx 2 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| EFSA_OpenFoodTox_EFSA_ReferencePoints.xlsx | NOAEL | =5 | mg/kg bw/day | Rat | oral: feed | 90 days | subchronic | EFSA CEF - 2015 - OutputID 2601 - clinical chemistry - systemic - Scientific Opinion on Flavouring Group Evaluation 86, Revision 2 (FGE.86Rev2): Consideration of aliphatic and arylalkyl amines and amides evaluated by JECFA (65th meeting) - doi:10.2903/j.efsa.2015.3998 |
| EFSA_OpenFoodTox_EFSA_ReferencePoints.xlsx | NOAEL | =5 | mg/kg bw/day | Rat | oral: feed | 90 days | subchronic | EFSA CEF - 2015 - OutputID 2601 - clinical chemistry - systemic - Scientific Opinion on Flavouring Group Evaluation 86, Revision 2 (FGE.86Rev2): Consideration of aliphatic and arylalkyl amines and amides evaluated by JECFA (65th meeting) - doi:10.2903/j.efsa.2015.3998 |
NTP_ICE_acute_oral 1 endpoint
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| NTP_ICE_acute_oral | LD50 | =514 | mg/kg bw | Rat | oral | acute | Rat Acute Oral Toxicity | NLM ChemIDplus TEST (undated); record_id=acute_oral_11603; row=5543; data_type=In Vivo; mixture=Chemical; chemical_name=Piperine; preferred_name=Piperine; dtxsid=DTXSID3021805; url=https://chem.nlm.nih.gov/chemidplus/; url_comptox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID3021805; url_cebs=https://doi.org/10.22427/NTP-DATA-DTXSID3021805; source_file=acute_oral.xlsx |
ToxValDB_EFSA 1 endpoint
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| ToxValDB_EFSA | NOAEL | =5 | mg/kg bw/day | Rat | oral | subchronic; 90 days | subchronic | LONG_REF=EFSA CEF (2015). Scientific Opinion on Flavouring Group Evaluation 86, Revision 2 (FGE.86Rev2): Consideration of aliphatic and arylalkyl amines and amides evaluated by JECFA (65th meeting). doi:10.2903/j.efsa.2015.3998.; TITLE=Scientific Opinion on Flavouring Group Evaluation 86, Revision 2 (FGE.86Rev2): Consideration of aliphatic and arylalkyl amines and amides evaluated by JECFA (65th meeting); AUTHOR=EFSA CEF; DOI=doi:10.2903/j.efsa.2015.3998; STORED_SOURCE_RECORD=https://clowder.edap-cluster.com/files/65201d30e4b0f0a60ddd1165; RECORD_SOURCE_LEVEL=Extraction document; SOURCE_URL=https://zenodo.org/record/5076033#.Y9fEoXbMI2z; YEAR=2015; ORIGINAL_YEAR=2015; TOXICOLOGICAL_EFFECT=clinical chemistry; TOXICOLOGICAL_EFFECT_CATEGORY=clinical chemistry; STUDY_GROUP=EFSA:15621567:M/F:--; QC_CATEGORY=Programmatically extracted from structured data source; Source overall passed QC, but this record was not manually checked; QC_STATUS=not determined; SOURCE_HASH=ToxValhc_3eae68dce81f0870bafe9e3a37c84311 |
openFDA substances 4 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| openFDA substances | FDA UNII substance identifier | U71XL721QK | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C17H19NO3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"U71XL721QK"} |
| openFDA substances | FDA UNII substance identifier | U71XL721QK | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C17H19NO3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"U71XL721QK"} |
| openFDA substances | FDA UNII substance identifier | U71XL721QK | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C17H19NO3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"U71XL721QK"} |
| openFDA substances | FDA UNII substance identifier | U71XL721QK | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C17H19NO3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"U71XL721QK"} |